Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure-Reference-Cited by-同舟云学术

Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

Published:2021-11 Issue:11 Volume:9 Page:807-820
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

McMurray John J.V.,Wheeler David C.,Stefánsson Bergur V.,Jongs Niels,Postmus Douwe,Correa-Rotter Ricardo,Chertow Glenn M.,Hou Fan Fan,Rossing Peter,Sjöström C. David,Solomon Scott D.,Toto Robert D.,Langkilde Anna Maria,Heerspink Hiddo J.L.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference19 articles.

1. Heart failure in end-stage kidney disease: pathophysiology, diagnosis, and therapeutic strategies;Rangaswami;Semin Nephrol,2018

2. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference;House;Kidney Int,2019

3. Updates in the management of heart failure for the chronic kidney disease patient;Hsu;Curr Opin Nephrol Hypertens,2019

4. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk In Communities (ARIC) study;Kottgen;J Am Soc Nephrol,2007

5. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies;Bansal;JAMA Cardiol,2017

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes;American Journal of Cardiovascular Drugs;2024-09-11

2. Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation;Journal of the American College of Cardiology;2024-09

3. Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan;Clinical Kidney Journal;2024-07-30

4. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis;The Lancet Diabetes & Endocrinology;2024-07

5. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21